The economic value of lamotrigine as a mood stabilizer: A U.S. managed care perspective

Managed Care Interface

Volumn 17, Issue 12, 2004, Pages 44-49

  Simons, W Robert ^a,b   Krishnan, Anu A ^b  

^a Global Hlth Econ Outcomes Res I   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CITALOPRAM; CLONAZEPAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; LAMOTRIGINE; LITHIUM CARBONATE; LITHIUM CITRATE; MOOD STABILIZER; OXACARBAZEPINE; PAROXETINE; PHENYTOIN; PRIMIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; COST CONTROL; DEPRESSION; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HOSPITALIZATION; HUMAN; LENGTH OF STAY; LOGISTIC REGRESSION ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MANIA; OUTCOMES RESEARCH; STATISTICAL MODEL; UNITED STATES;

ADULT; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; COST-BENEFIT ANALYSIS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; LENGTH OF STAY; LONGITUDINAL STUDIES; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); TREATMENT OUTCOME; TRIAZINES;

EID: 11144229491     PISSN: 10965645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Judd LL, Akiskal HS, Schettler PJ, et al: The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530-537.
2. Calabrese JR, Hirschfield RM, Reed M, et al: Impact of bipolar disorder on a U.S. community sample. J Clin Psychiatry 2003;64:425-432.
3. Hirschfield R, Calabrese JR, Reed M, et al: Burden of manic versus depressive symptoms in patients with bipolar disorder (poster). Presented at the 156th annual meeting of the American Psychiatric Association. San Francisco, May 17-22, 2003.
4. Bauer MS, Kirk GF, Gavin C, et al: Determinants of functional outcome and healthcare costs in bipolar disorder: A high-intensity follow-up study. J Affect Disord 2001;65:231-241.
5. Begley CE, Annegers JF, Swann AC, et al: The lifetime cost of bipolar disorder in the U.S: An estimate for new cases in 1998. Pharmacoeconomics 2001;19:483-495.
6. Bowden CL, Krishnan AA: Pharmacotherapy for bipolar depression: An economic assessment. Expert Opinon Pharmacother 2004;5:1101-1107.
7. Frye MA, Ketter TA, Leverich GS, et al: The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000;61:9-15.
8. McIntyre RS, Mancini D, Parikh S, et al: Lithium revisited. Can J Psychiatry 2001;46:322-327.
9. Maj M, Pirozzi R, Magliano L, et al: Long-term outcome of lithium prophylaxis in bipolar disorder: A 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998;155:30-35.
10. Mullen J, Jibson MD, Sweitzer D: A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: The quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 2001;23:1839-1854.
11. Compton MT, Nemeroff CB: The treatment of bipolar depression. J Clin Psychiatry 2000;61(suppl 9):57-67.
12. Bowden CL: Bipolar disorder review. Presented at the 15th European College of Neuropsychopharmacology Congress. Barcelona, Spain, October 5-9, 2002.
13. Calabrese JR, Suppes T, Bowden CL, et al: A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 2000;61:841-850.
14. Bowden CL, Calabrese JR, Sachs G, et al: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar 1 disorder. Arch Gen Psychiatry 2003;60:392-400.
15. Calabrese JR, Bowden CL, Sachs G, et al: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psych 2003;64:1013-1024.
16. Goodwin GM, Bowden CL, Calabrese JR, et al: A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance treatment in bipolar I disorder. J Clin Psychiatry 2004;65:432-441.
17. American Psychiatric Association: Practice guidelines for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159:1-50.
18. Bowden CL, Karren NU: Lamotrigine in the treatment of bipolar disorder. Expert Opin Pharmacother 2002;3:1513-1519.
19. Treatment and economic outcomes in patients with bipolar disorder (abstract). Presented at the 16th European College of Neuropsychopharmacology Congress. Prague, Czech Republic, September 20-24, 2003.
20. International Classification of Diseases Ninth Revision, vol 1, chap 5 (mental disorders), Geneva, Switzerland, World Health Organization, 1998.
21. The LIFEREG procedure, in SAS/STAT® User's Guide, Version 8. Cary, NC, SAS Institute Inc., 1999.
22. Tobin J: Estimation of relationships for limited dependent variables. Econometrical 1958;26:24-36.
23. Maddala GS: Censored and truncated regression models, in Limited Dependent and Qualitative Variables in Econometrics. Cambridge, MA, Cambridge University Press, 1983; 160.
24. Yatham LN, Kusumakar V, Calabrese JR, et al: Third generation anticonvulsants in bipolar disorder: A review of efficacy and summary of clinical recommendations. J Clin Psychiatry 2002;63:275-283.